Immune-Onc Therapeutics Adds Paul Woodard and An Song to C-Suite

Paul Woodard has joined Immune-Onc Therapeutics as its chief medical officer. He comes to the Palo Alto, CA-based cancer immunotherapy developer from Bellicum Pharmaceuticals (NASDAQ: [[ticker:BLCM]]), where he was senior vice president of clinical and medical affairs. In other moves, Immune-Onc promoted An Song to chief scientific officer. Song was the company’s senior vice president of development sciences. Immune-Onc’s lead program is being developed as a potential treatment for acute myeloid leukemia and other cancers.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan